MARKET

GRCL

Gracell Biotechnologies Inc.
GRCL
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-20.3363
2070.00
4.429
989,866,864.25
Weekly Report: what happened at GRCL last week (0226-0301)?
Weekly Report · 03/04 09:06
Weekly Report: what happened at GRCL last week (0219-0223)?
Weekly Report · 02/26 09:06
Gracell Biotechnologies Price Target Cut to $10.25/Share From $11.00 by Stifel
Dow Jones · 02/22 14:41
Gracell Biotechnologies Cut to Hold From Buy by Stifel
Dow Jones · 02/22 14:41
Stifel Downgrades Gracell Biotechnologies to Hold, Lowers Price Target to $10.25
Benzinga · 02/22 14:31
Gracell Biotechnologies Acquisition Completed
Gracell Biotechnologies Inc. Announced the completion of its previously announced agreement to be acquired by AstraZeneca. The company is a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease. The acquisition was structured as a merger of the two companies.
Barchart · 02/22 07:45
AstraZeneca Deal For Gracell Biotechnologies Closing Tomorrow (Includes CVR)
Seeking Alpha · 02/21 16:51
Gracell Biotechnologies receives shareholder approval for merger with AstraZeneca
Healthcare M&A Gracell Biotechnologies receives shareholder approval for merger with AstraZeneca. The China-based biopharmaceutical company and the UK-based company are expected to close the merger in February. Gracell's shareholders approved the proposed merger by 99.9% of votes cast.
Seeking Alpha · 02/20 13:09
More

Webull offers Gracell Biotechnologies Inc. stock information, including NASDAQ: GRCL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRCL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRCL stock methods without spending real money on the virtual paper trading platform.